The proteomic test identifies prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The deal is the latest coverage and reimbursement success for the Cambridge, Massachusetts-based urology diagnostics firm.
Medicare contractors Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all proposed reimbursement coverage for the ProMark test.
The companies have also agreed to co-develop a second-generation version of the assay, which will run on Hologic's Panther instrument system.
The study, by Fred Hutchinson researchers consulting with Metamark, found the test offers increased quality-adjusted life-years and a decrease in costs.
The funding will be used to further expand the company's clinical testing products and services in the US and abroad.
The deal provides access to Metamark's diagnostic and prognostic tests for urology to 5.2 million Highmark Blue Shield members in Delaware, Pennsylvania, and West Virginia.
Since launching it in June, the firm has sold roughly 1,000 tests. It measures eight proteins to determine the likelihood that a patient's cancer is aggressive.
The laboratory will serve as the primary processor for the company's protein-based prostate cancer test called ProMark.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.